Form 4: Lexaria Bioscience Director Nicholas Baxter Reports Acquisition of Stock Options
SEC Form 4
Director Nicholas Baxter reports acquisition of 5,000 stock options in Lexaria Bioscience Corp.
Summary
- On April 26, 2024, Nicholas W Baxter, a director of Lexaria Bioscience Corp., acquired 5,000 stock options with an exercise price of $2.36, exercisable from April 26, 2024, to April 26, 2029.
- This transaction increased his direct holdings of derivative securities to 40,000 stock options.
- He also disposed of 11,000 common shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reflects a routine transaction. The acquisition of options is mildly positive, while the disposal of shares is mildly negative.
Positives
- The acquisition of stock options by a director could be seen as a positive signal, indicating confidence in the company's future performance.
Negatives
- The disposal of 11,000 common shares by a director could be seen as a negative signal.
Industry Context
This filing is a routine disclosure related to insider transactions and provides insight into the actions of company leadership, which can influence investor sentiment.
Stakeholder Impact
- The transaction could influence shareholder perception of the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 04/26/2021 | Date of exercisable stock options with an exercise price of $3.00 and an expiration date of 04/26/2026 for 1,500 common shares. |
| 06/08/2021 | Date of exercisable stock options with an exercise price of $3.00 and an expiration date of 06/08/2026 for 5,000 common shares. |
| 09/01/2021 | Date of exercisable stock options with an exercise price of $3.00 and an expiration date of 09/01/2026 for 1,900 common shares. |
| 03/08/2022 | Date of exercisable stock options with an exercise price of $3.39 and an expiration date of 03/08/2027 for 3,400 common shares. |
| 10/12/2022 | Date of exercisable stock options with an exercise price of $1.96 and an expiration date of 10/12/2027 for 18,200 common shares. |
| 05/09/2023 | Shareholder approval received for repricing of stock options. |
| 07/25/2023 | Date of exercisable stock options with an exercise price of $0.87 and an expiration date of 07/25/2028 for 5,000 common shares. |
| 04/26/2024 | Date of transaction: Nicholas Baxter acquired 5,000 stock options with an exercise price of $2.36, expiring on 04/26/2029. |
| 04/26/2029 | Expiration date of the 5,000 stock options acquired on 04/26/2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.